ANRO (Alto Neuroscience) EV-to-EBIT : 1.42 (As of May. 17, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alto Neuroscience's Enterprise Value is $-85.50 Mil. Alto Neuroscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-60.06 Mil. Therefore, Alto Neuroscience's EV-to-EBIT for today is 1.42.

The historical rank and industry rank for Alto Neuroscience's EV-to-EBIT or its related term are showing as below:

ANRO' s EV-to-EBIT Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.42
Current: 1.42

During the past 4 years, the highest EV-to-EBIT of Alto Neuroscience was 1.42. The lowest was 0.00. And the median was 0.00.

ANRO's EV-to-EBIT is ranked better than
57.59% of 474 companies
in the Biotechnology industry
Industry Median: 6.81 vs ANRO: 1.42

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alto Neuroscience's Enterprise Value for the quarter that ended in Dec. 2024 was $-37.13 Mil. Alto Neuroscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-60.06 Mil. Alto Neuroscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 161.75%.

Alto Neuroscience EV-to-EBIT Historical Data

The historical data trend for Alto Neuroscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience EV-to-EBIT Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

0.62

Alto Neuroscience Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial					-	-5.28	-2.17	-2.56	0.62

Competitive Comparison of Alto Neuroscience's EV-to-EBIT

For the Biotechnology subindustry, Alto Neuroscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Alto Neuroscience EV-to-EBIT Calculation

Alto Neuroscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-85.500	/	-60.056
	=	1.42

Alto Neuroscience's current Enterprise Value is $-85.50 Mil.
Alto Neuroscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.06 Mil.

Alto Neuroscience (NYSE:ANRO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alto Neuroscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 )	=	EBIT	/	Enterprise Value (Q: Dec. 2024 )
	=	-60.056	/	-37.12999
	=	161.75 %

Alto Neuroscience's Enterprise Value for the quarter that ended in Dec. 2024 was $-37.13 Mil.
Alto Neuroscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.06 Mil.

Alto Neuroscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

650 Castro Street, Suite 450, Mountain View, CA, USA, 94041

Website

https://www.altoneuroscience.com

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.